In bladder cancer (BC), MYC serves as a novel substrate of SETD8 to be methylated at lysine 412, which enhances MYC protein stability by preventing the CHIP‐mediated degradation and ultimately promotes tumor growth. The gene discussed is KMT5A; the disease is urinary bladder carcinoma.